Oncolytic viruses (OVs) are effective anti-cancer agents, however their abilities to induce anti-tumor immunity are not yet optimal. Mutanome epitopes are a novel source of tumor antigen formed as a result of mutations within the tumor genome. Within this project we attempted to combine B16F10 mutanome vaccination with OV therapy. We confirmed previous findings that significant immune responses to these epitopes can be generated. Furthermore, we designed and cloned a multi-epitope mutanome construct into MG1 Maraba virus and E1-/E3- deleted type 5 Adenovirus to use for heterologous prime-boost vaccination. While we demonstrated that these viruses induced T-cell responses to one mutanome epitope, we failed to detect responses to the other epitopes. Furthermore there was no effect seen on overall survival. This approach warrants further investigation because coupling mutanome vaccination with OV therapy has the potential to exploit the therapeutic effects of the OV while inducing anti-tumor immunity to tumor-unique antigens.

As vacinas antimeningocócicas têm se demonstrado efetivas contra os sorogrupos A e C, no entanto ainda não existe vacina contra o sorogrupo B devido à similaridade entre a estrutura capsular do polissacáride B e o ácido polisiálico que faz parte do tecido cerebral humano, podendo levar à autoimunidade. O objetivo deste estudo foi investigar as propriedades adjuvantes dos toxóides Stx1 e Stx2 (STEC) de Escherichia coli, administrados em preparações antigênicas com vesículas de membrana externa nativa (NOMV) de Neisseria meningitidis B, comparando duas vias de imunização prime-boost ou intramuscular, em camundongos BALB/c com idade entre 6-8 semanas. A determinação dos níveis de anticorpos empregando a técnica de ELISA, mostrou elevadas concentrações de anticorpos IgG em soros de animais imunizados pela via intramuscular com Stx1+NOMV, mas não com NOMV, o que sugere que por esta via (intramuscular apenas) Stx1 possa ter atuado como adjuvante. No ensaio de Immunoblotting, soros de animais imunizados com Stx1+NOMV reconheceram maior número de antígenos de NOMV quando comparado ao grupo que recebeu Stx2+NOMV. O sistema prime-boost mostrou-se efetivo quando comparamos os níveis de anticorpos presentes no soro após a dose intramuscular (reforço), entretanto, não melhor do que quando utilizamos duas doses apenas pela via intramuscular. Este estudo poderá contribuir no desenvolvimento de tecnologias associadas a novas preparações antigênicas utilizando antígenos de membrana externa de N. meningitidis B , empregando toxóides como adjuvantes. / The meningococcal vaccines have been shown to be effective against serogroups A and C, however there is still no vaccine against serogroup B. The capsular polysaccharide from serogroup B meningococci polysialic acid moiety mimetic of many human glycoproteins including the neural cell adhesion molecules and may lead to autoimmunity. This study aimed to investigate the adjuvant properties of toxoids Stx1 and Stx2 (STEC) from Escherichia coli and native outer membrane vesicles (NOMV) of Neisseria meningitidis B, comparing two ways of immunization prime-boost or only intramuscular in BALB/c mice. The results showed high concentrations of IgG antibodies in sera of animals immunized intramuscularly with Stx1+NOMV, suggesting that in this way may have Stx1 acted as an adjuvant. In the Immunoblotting assay, sera from animals immunized with Stx1+NOMV recognized more antigens of NOMV when compared to the group that received Stx2+NOMV. The prime-boost was effective however, no better than only two doses intramuscularly. This study may contribute to the development of new technologies and strategies against N. meningitidis B employing toxoids as adjuvants.

As vacinas antimeningocócicas têm se demonstrado efetivas contra os sorogrupos A e C, no entanto ainda não existe vacina contra o sorogrupo B devido à similaridade entre a estrutura capsular do polissacáride B e o ácido polisiálico que faz parte do tecido cerebral humano, podendo levar à autoimunidade. O objetivo deste estudo foi investigar as propriedades adjuvantes dos toxóides Stx1 e Stx2 (STEC) de Escherichia coli, administrados em preparações antigênicas com vesículas de membrana externa nativa (NOMV) de Neisseria meningitidis B, comparando duas vias de imunização prime-boost ou intramuscular, em camundongos BALB/c com idade entre 6-8 semanas. A determinação dos níveis de anticorpos empregando a técnica de ELISA, mostrou elevadas concentrações de anticorpos IgG em soros de animais imunizados pela via intramuscular com Stx1+NOMV, mas não com NOMV, o que sugere que por esta via (intramuscular apenas) Stx1 possa ter atuado como adjuvante. No ensaio de Immunoblotting, soros de animais imunizados com Stx1+NOMV reconheceram maior número de antígenos de NOMV quando comparado ao grupo que recebeu Stx2+NOMV. O sistema prime-boost mostrou-se efetivo quando comparamos os níveis de anticorpos presentes no soro após a dose intramuscular (reforço), entretanto, não melhor do que quando utilizamos duas doses apenas pela via intramuscular. Este estudo poderá contribuir no desenvolvimento de tecnologias associadas a novas preparações antigênicas utilizando antígenos de membrana externa de N. meningitidis B , empregando toxóides como adjuvantes. / The meningococcal vaccines have been shown to be effective against serogroups A and C, however there is still no vaccine against serogroup B. The capsular polysaccharide from serogroup B meningococci polysialic acid moiety mimetic of many human glycoproteins including the neural cell adhesion molecules and may lead to autoimmunity. This study aimed to investigate the adjuvant properties of toxoids Stx1 and Stx2 (STEC) from Escherichia coli and native outer membrane vesicles (NOMV) of Neisseria meningitidis B, comparing two ways of immunization prime-boost or only intramuscular in BALB/c mice. The results showed high concentrations of IgG antibodies in sera of animals immunized intramuscularly with Stx1+NOMV, suggesting that in this way may have Stx1 acted as an adjuvant. In the Immunoblotting assay, sera from animals immunized with Stx1+NOMV recognized more antigens of NOMV when compared to the group that received Stx2+NOMV. The prime-boost was effective however, no better than only two doses intramuscularly. This study may contribute to the development of new technologies and strategies against N. meningitidis B employing toxoids as adjuvants.

Le Syndrome Dysgénésique et Respiratoire Porcin (PRRS) est la maladie infectieuse endémique la plus couteuse en élevage porcin dont l'agent responsable est un Arterivirus, le PRRSV, qui présente une grande diversité génétique. L'infection par le PRRSV est fréquemment associée à l'infection par les virus influenza. La vaccination est une méthode de lutte adaptée contre ces virus. Dans le cas du PRRSV, les vaccins les plus utilisés sont des virus vivants modifiés (MLV) qui induisent une immunité protectrice peu efficace contre les variants viraux. Dans le cas du virus influenza, les vaccins inactivés utilisés présentent la même insuffisance.Dans ce travail de thèse, j'ai évalué des stratégies vaccinales visant à induire une immunité efficace contre des variants viraux, en utilisant des antigènes conservés entre souches, adressés aux cellules présentatrices d'antigènes (APC), et j'ai analysé l'effet de différentes voies et modes d'administration.Dans le cas du virus grippal, le ciblage d'antigènes conservés (HA2, M2e, NP) au CD11c a permis d'augmenter la réponse T uniquement lors d'administration par voie intramusculaire (IM) et fut sans effet sur la réponse anticorps. La vaccination par voie intradermique s'est traduit par une exacerbation de la pathologie lors d'une épreuve virale, alors que la vaccination par voie IM a réduit les symptômes, la durée d'excrétion virale en corrélation avec une meilleure réponse anticorps anti-HA2 et M2e.Dans le cas du virus PRRSV qui fut mon sujet principal d'étude, j'ai cherché à optimiser des réponses lymphocytaires T IFNγ en employant une stratégie vaccinale ADN codant des antigènes contenant des épitopes T conservés entre souches, ciblés aux APC. En effet, alors que les mutations virales conduisent à un échappement aux anticorps neutralisants, la réponse lymphocytaire T IFNγ a été proposée impliquée dans la protection croisée. J'ai montré que l'immunogénicité optimale de vaccins ADN PRRSV, conduisant à la réponse T la plus large, est obtenue par l'administration intradermique associée aux nanoparticules de PLGA (NP), suivi d'une électroporation (EP), par rapport à EP seul ou délivrance intradermique ou transcutanée avec des patches à micro-aiguilles résorbables. Cette immunogénicité optimale est associée à une bonne transfection des cellules de la peau, à une accumulation de cellules inflammatoires, et à une mobilisation des cellules dendritiques. J'ai ensuite utilisé ce mode d'administration EP+NP pour immuniser des porcs avec des plasmides codant des antigènes conservés du PRRSV adressés ou non aux APC via CD11c ou XCR1. Les porcs ont été immunisés soit avec des injections répétées d'ADN seul soit en prime-boost ADN-MLV. Le régime ADN-MLV s'est montré supérieur pour l'induction de réponse B et T à celui de l'ADN ou du MLV seuls, et le ciblage aux APC a nettement augmenté la réponse anticorps mais pas la réponse T IFNγ. Dans une expérience suivante à visée d'application sur le terrain, j'ai utilisé le régime ADN-MLV (sans NP cette fois), délivré avec EP ou avec jet sous pression (PJ). Dans ces conditions, la primo-vaccination avec ADN n'a pas significativement augmenté la réponse T IFNγ induite par le MLV, mais elle a clairement augmenté la réponse anticorps avec un bénéfice du ciblage des APC. L'immuno-potentialisation induite par la primo-vaccination ADN n'a pas conduit à l'amélioration de la protection contre une épreuve avec un virus hétérologue et a montré que cette protection n'est au final pas corrélée avec la réponse lymphocytaire T IFNγ et opère en l'absence d'anticorps neutralisants détectables. Enfin, l'ensemble de ce travail montre que l'effet du ciblage des APC chez le porc est influencé par la voie d'administration et par le régime d'administration comme le prime-boost ADN-MLV. / The Porcine Reproductive and Respiratory Syndrome (PRRS) is the most damaging infectious disease in pigs worldwide. The etiologic agent is an Arterivirus, the PRRSV, which presents a large genetic diversity. PRRSV infection is frequently associated with influenza virus co-infection. Vaccination is a highly suitable way to control these viruses. In the case of PRRSV, the most effective commercial vaccines are modified live vaccines (MLV) which induce only a partial protection against heterologous strains. In the case of the influenza virus, the available inactivated vaccines show the same weakness.With the goal to control emerging influenza and PRRSV variants, I evaluated vaccine strategies involving conserved viral antigens between strains which were targeted to antigen-presenting cells (APC) and delivered by different routes and methods.In the case of influenza virus, the targeting of conserved antigens (HA2, M2e and NP) to CD11c led to increased IFNγ T cell responses only when vaccines were delivered by the intramuscular (IM) route and had no effect on the humoral response. The intradermal route exacerbated disease following challenge whereas the IM route reduced the symptoms, the duration of viral excretion in correlation with higher anti-HA2 and anti-M2e antibody responses.In the case of PRRSV, which was my main subject, I sought to optimize the IFNγ T cell responses by using DNA vaccines encoding antigens with conserved T-epitopes between strains, and targeted to APC. Indeed, whereas viral mutants escape neutralizing antibodies, it has been proposed that the IFNγ T cell responses are instrumental for cross-protection. I showed that the broadest T cell responses were induced by DNA vaccines combined to nanoparticles PLGA (NP) injected by the intradermal route, followed by electroporation (EP) compared with EP-only, intradermal route-only or transcutaneous dissolvable microneedles. This optimal immunogenicity was associated with a high transfection level of skin cells, an accumulation of inflammatory cells, and dendritic cells mobilisation. Next I used the EP+NP method to immunize pigs with plasmids encoding conserved PRRSV antigens targeted or not to APC via CD11c or XCR1. Pigs were immunized either with repeated injections of DNA alone or with a prime-boost DNA-MLV. The DNA-MLV regimen induced improved humoral and IFNγ T cell responses compared to DNA alone or MLV alone and the APC-targeting significantly increased the humoral response but not the IFNγ T cell response. Finally, I evaluated the DNA-MLV regimen efficacy, with an applied perspective, using naked DNA without NP and delivered by EP or by a convenient needle free injection technology (PJ). In these conditions, the DNA prime did not significantly increase the IFNγ T cell response induced by the MLV, but clearly increased the humoral response with a benefit of the APC-targeting. However, the immune potentiation induced by the DNA prime did not lead to an improved protection following a heterologous challenge. The heterologous protection was not correlated to the measured humoral and IFNγ T cell responses, and neutralizing antibodies were undetectable. Thus cross-protective effectors have not been sufficiently activated by our DNA-MLV strategy and the immune correlates of protection against heterologous PRRSV are still to be identified to develop cross-protective vaccines. Finally, this work shows that the effect of APC-targeting in pigs is influenced by delivery routes and methods and by vaccine regimen such as the prime-boost DNA-MLV.

Submitted by Maria Beatriz Vieira (mbeatriz.vieira@gmail.com) on 2017-08-29T11:52:09Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) dissertacao_thais_larre_oliveira.pdf: 616408 bytes, checksum: 404ac55ee19b90246334aac10658a361 (MD5) / Approved for entry into archive by Aline Batista (alinehb.ufpel@gmail.com) on 2017-08-29T19:49:36Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) dissertacao_thais_larre_oliveira.pdf: 616408 bytes, checksum: 404ac55ee19b90246334aac10658a361 (MD5) / Approved for entry into archive by Aline Batista (alinehb.ufpel@gmail.com) on 2017-08-29T19:49:43Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) dissertacao_thais_larre_oliveira.pdf: 616408 bytes, checksum: 404ac55ee19b90246334aac10658a361 (MD5) / Made available in DSpace on 2017-08-29T19:49:54Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) dissertacao_thais_larre_oliveira.pdf: 616408 bytes, checksum: 404ac55ee19b90246334aac10658a361 (MD5) Previous issue date: 2014-08-07 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES / A leptospirose é uma doença infecciosa emergente causada por espiroquetas patogênicas do gênero Leptospira, com complicações humana e veterinária. Essa doença é transmitida através do contato direto com um animal reservatório ou com o ambiente contaminado com a urina destes animais. O desenvolvimento de vacinas seguras e multivalentes contra leptospirose, que substituam as bacterinas existentes, permanece um desafio. Bacterinas são reatogênicas e conferem imunidade sorovar-específica e de curta duração. Esforços para o desenvolvimento de vacinas recombinantes tem focado em proteínas de membrana externa (OMPs). A proteína de membrana externa OmpL37 é conservada entre diferentes sorovares de Leptospira e atua na adesão aos tecidos do hospedeiro. Neste estudo, nós relatamos pela primeira vez, a avaliação do potencial imunoprotetor de OmpL37 como antígeno vacinal em hamsters, sob diferentes estratégias: vacina de subunidade, vacina de DNA e prime-boost. A caracterização da resposta imune através de ELISA indireto e qRT-PCR demonstrou que os maiores níveis de IgG foram estimulados pela vacina de subunidade, a qual também induziu resposta inflamatória. A vacina de DNA falhou em induzir imunidade humoral, porém também estimulou TNF-α. Apesar da resposta induzida, nenhuma formulação protegeu significativamente os animais contra a doença. / Leptospirosis is an emerging infectious disease caused by pathogenic spirochetes of Leptospira genus, of human and veterinary concern. This infectious disease is transmitted through direct contact with an animal reservoir or an environmental contaminated with their urine. The development of safe and multivalent vaccines against leptospirosis, which replace existing bacterins, remains a challenge. Bacterins are reactogenic and afford serovar specific and short-term immunity. Efforts to develop recombinant vaccines against leptospirosis have focused on outer membrane proteins (OMPs). The outer membrane protein OmpL37 is conserved among different Leptospira serovars and plays a role in adherence to host tissues. In this study we report for the first time, the evaluation of OmpL37 immunoprotective potential as a vaccine antigen in hamsters, under different strategies: subunit vaccine, DNA vaccine and prime-boost. The characterization of the immune response by indirect ELISA and qRT-PCR showed that higher levels of IgG were stimulated by the vaccine subunit, which also induced an inflammatory response. The DNA vaccine failed to induce humoral immunity, but also stimulated TNF-α. Despite the induced response, no formulation significantly protected the animals against the disease.

Streptococcus mutans is the main causative agent of dental caries, which is a widespread infectious disease. A number of surface molecules are involved in the pathogenicity of this organism, including adherence and aggregation factors. The wall-associated protein A (WapA) of Streptococcus mutans GS-5 was previously demonstrated to be a sucrose-dependent adherence and aggregation factor, and is a larger precursor to extracellular antigen A (AgA), a candidate antigen for a dental caries vaccine.The full-length wapA gene and a C-terminal truncated version agA encoding the AgA were cloned into the mammalian expression vector pcDNA 3.1/V5/His-TOPO. The above constructs were mixed with a cationic lipid and used to transfect Chinese hamster ovary (CHO) cells. Transient expression of the wapA and agA genes was observed at 24 h post-transfection, as shown by Western immunoblot analysis. In CHO, cells WapA containing the membrane and wall-spanning region was found in apoptotic bodies, whereas the soluble AgA, which lacked the hydrophobic region, was found in extracellular medium. A higher salivary IgA level was observed in mice immunized with the pcDNA-wapA vaccine as compared to those immunized with the pcDNA-agA vaccine. Furthermore, the anti-WapA antibody inhibited S. mutans sucrose-dependent adherence, suggesting potential protection of the tooth against S. mutans colonization, while anti-AgA had no significant effect. Indeed, prediction and analysis of protein epitopes showed that WapA contains highly promiscuous MHC-II binding motifs that are absent from AgA. Immunodot assay confirmed that WapA bound biotin-labeled dextran, whereas AgA did not.

Développement et évaluation de nouvelles stratégies pour le traitement des hépatites B chroniques, dans le modèle du canard de Pékin infecté par le DHBVL’infection chronique par le HBV est la cause majeure de cirrhose hépatique et de carcinome hépatocellulaire, conduisant à plus d’un million de décès chaque année. Le faible taux de réussite des thérapies actuelles des hépatites B montre la nécessité du recours à des méthodes thérapeutiques alternatives. Ainsi, nous avons étudié une stratégie pertinente reposant sur l’utilisation de molécules antisens (PNAs) couplées à des peptides perméabilisants (CPPs). Nous avons démontré que les PNAs ciblant le signal d’encapsidation du DHBV couplés au CPP pénétraient dans les cellules et conduisait à une inhibition de la réplication virale. De plus, nous avons mis en évidence une activité antivirale du CPP (Arg)8 seul. Nous avons ensuite évaluer le mécanisme d’action antivirale du CPP in vitro et avons démontré qu’il inhibait les stades tardifs de la morphogénèse virale, conduisant à une inhibition forte de la sécrétion des particules virales. Par ailleurs, nous nous sommes intéressés à l’évaluation de stratégies immunothérapeutiques, reposant sur la vaccination génétique. Nous avons démontré les bénéfices de la co-administration de cytokines (IFNγ), avec un vaccin à ADN dirigé contre la grande protéine d’enveloppe du DHBV (preS/S), sur l’amplitude de la réponse humorale et sur le pouvoir neutralisant des anticorps induits. Enfin nous avons évalué les bénéfices d’une approche d’immunisation hétérologue « prime-boost » associant l’immunisation à ADN et un vecteur viral (AdénoCELO) recombinant, codant la protéine preS/S du DHBV et l’IFNγ. Nous avons montré que l’immunisation hétérologue induisait une réponse humorale plus forte que celle induite par l’immunisation homologue. / Development and evaluation of new strategies for treating chronic hepatitis B in the model of Peking duck infected with DHBVChronic infection with Hepatitis B virus (HBV) is the major cause of liver cirrhosis and hepatocellular carcinoma, leading to more than one million deaths each year. The low success rate of current therapies against HBV infection shows the need of alternative therapeutics. Thus, we studied a new strategy based on the use of antisense molecules (PNAs) coupled with cell penetrating peptides (CPPs). We have shown that PNAs targeting the DHBV encapsidation signal coupled to CPPs penetrated into the cells and led to an inhibition of viral replication. In addition, we have demonstrated an antiviral activity of the CCP (Arg)8 itself. We then evaluate the mechanism of antiviral action of this CPP in vitro and have shown that it inhibited the late stages of viral morphogenesis, leading to a strong inhibition of the release of viral particles. Furthermore, we were interested in evaluating immunotherapeutic strategies, based on DNA vaccination. We have demonstrated the benefits of co-administration of cytokines (IFNy), with a DNA vaccine directed against the DHBV large envelope protein (preS/S), enhancing the magnitude of humoral response and enhancing neutralizing anti-DHBV antibody response. Finally we evaluated the benefits of a heterologous immunization approach or prime-boost immunization involving DNA vaccination and a recombinant viral vector (AdenoCELO) encoding the DHBV preS/S and IFNy proteins. We have shown that heterologous immunization induced a humoral response stronger than that induced by homologous immunization. By contrast, the heterologous prime-boost strategy was less effective than homologous DNA immunization for therapy of chronic DHBV-carrier ducks.

Memory CD8 T cells offer increased protection to immune hosts by rapidly eliminating pathogen-infected cells during re-infection. Generating and sustaining a protective memory CD8 T cell response is considered a hallmark of adaptive immunity. Extensive research has been devoted to understanding the parameters affecting memory CD8 T cell generation after infection or immunization in order to design the most effective vaccines. An accepted notion in the field is that increased protection from re-infection is afforded by the generation of a large number of memory CD8 T cells. Consecutive prime-boost immunization strategies that elicit secondary responses are often used to increase the absolute numbers of memory CD8 T cells. While parameters affecting the generation of primary memory CD8 T cells are well known, the factors influencing the development of re-stimulated secondary CD8 T cell responses remain understudied. Here, I addressed the mechanisms involved in the generation and development of secondary memory CD8 T cells. I found that the time at which primary memory CD8 T cells enter into an immune response during re-infection impacts their fate and differentiation into secondary memory CD8 T cells. Late-entry of primary memory CD8 T cells into an immune response (relative to the initiation of infection) not only facilitates expression of transcription factors associated with memory formation in secondary effector CD8 T cells, but also influences the ability of secondary memory CD8 T cells to localize within the lymph nodes, produce interleukin-2 cytokine (IL-2), and undergo robust antigen-driven proliferation. The timing of stimulation of primary memory CD8 T cells also impacts the duration of expression of the high-affinity IL-2 receptor (CD25) on secondary effector CD8 T cells and their sensitivity to IL-2 signaling. Importantly, by blocking or enhancing IL-2 signaling in developing secondary CD8 T cells, I verify the role of IL-2 in controlling the differentiation of secondary CD8 T cell responses. The data I present herein suggest that the process of primary memory-to-secondary memory CD8 T cell differentiation is not fixed and can be manipulated, a notion with implications in the design of future prime-boost vaccination approaches. Although vaccines are designed and intended to benefit a range of individuals, at times the efficacy of a vaccination regime depends on the overall health status of a host. Thus, in another portion of my thesis work I explored the extent to which obesity compromises the differentiation and maintenance of protective memory CD8 T cell responses. I found that diet-induced obesity did not impact the maintenance of pre-existing memory CD8 T cells, including their acquisition of a long-term memory phenotype (i.e., CD27hi, CD62Lhi, KLRG1low) and function (i.e., cytokine production, antigen-driven secondary expansion, and memory CD8 T cell-mediated protection). Additionally, diet-induced obesity did not influence the differentiation and maintenance of newly evoked memory CD8 T cell responses, in inbred and outbred hosts, that were generated in response to different types of systemic (LCMV, L. monocytogenes) and/or localized (influenza virus) infections. Interestingly, I found that the rate of naïve-to-memory CD8 T cell differentiation after a peptide-coated dendritic cell immunization was similar in lean and obese hosts. This suggests that obesity-associated inflammation is unlike pathogen- or adjuvant-induced inflammation, and does not influence the development of an endogenous memory CD8 T cell response. My studies reveal that the obese environment does not influence the development or maintenance of memory CD8 T cell responses that are either primed before or after obesity is established. This is a surprising notion with implications for future studies aiming to elucidate the role of obesity in susceptibility to infection and vaccine efficacy. Collectively, the data presented here further the understanding of memory CD8 T cell responses in contexts of health and disease.

A cárie dental é uma doença bacteriana infecciosa considerada como um dos principais problemas de saúde pública. O principal agente etiológico para o desenvolvimento da doença é o Streptococcus mutans. A proteína P1, também conhecida como antígeno I/II, do S. mutans é fundamental para a etapa inicial de adesão à superfície dental (sacarose-independente), sendo, portanto, considerada essencial para o processo de colonização deste patógeno. Algumas regiões dessa proteína vêm sendo empregadas como antígenos em estratégias vacinais contra a cárie, entre elas a região A, localizada na porção N-terminal, conhecida como região de ligação à saliva Saliva Binding Region (SBR). No entanto, apesar dos avanços, não existe vacina para a prevenção da cárie licenciada para uso em humanos. Diante disso, o presente trabalho tem como objetivo o desenvolvimento e caracterização de uma nova estratégia vacinal contra o S. mutans baseada em esquema de dose-reforço heterólogo, utilizando o fragmento P139-512, na forma de proteína purificada, expressa a partir de linhagens recombinantes de Bacillus subtilis. A proteína P139-512 compreende os aminoácidos 39-512 da proteína nativa, o que corresponde a toda região A e uma pequena porção da região variável da proteína P1. Utilizamos esporos de B. subtilis 1012, modificados para expressar o antígeno P139-512 (LDV702). A linhagem LDV704, além de expressar o antígeno, foi modificada para expressar uma invasina (InvA) com capacidade de se ligar a epitélios de mucosa. Camundongos da linhagem BALB/c foram imunizados por via sublingual com uma dose de esporos de B. subtilis (linhagens 1012, LDV702, LDV704 ou PBS) seguidos por dois reforços com a proteína P139-512, associada ou não com o adjuvante LTK63. Níveis significativos de anticorpos séricos foram induzidos pelas formulações em associação com o adjuvante após a terceira dose, e mostraram-se capazes de reconhecer os epítopos em diferentes linhagens de S. mutans. No entanto, nenhuma das formulações mostrou-se capaz de ativar respostas de mucosa (S-IgA). Porém, observamos que o adjuvante LTK63 empregado na estratégia dose-reforço heterólogo potencializou a resposta sérica de anticorpos IgG, sendo capaz de modular e melhorar qualitativamente as respostas induzidas. Assim, a administração das formulações na presença do adjuvante representa uma alternativa promissora para o controle do S. mutans. / Dental caries is an infectious bacterial disease considered as one of the main public health problems. The main etiological agent for the development of the disease is the Streptococcus mutans. The P1 protein, also known as S. mutans Ag I / II antigen, is essential for the initial stages of adhesion to the dental surface (sucrose-independent) and is, therefore, considered essential for the colonization process of this pathogen. Some regions of this protein have been used as antigens in vaccine strategies against caries, among them the A region, located at the amino terminal region also known as the Saliva Binding Region (SBR). However, despite the advances, there is no licensed anti-caries vaccine for human use. Therefore, the present work aims to develop and characterize a new vaccine strategy against S. mutans based on a heterologous priming/boost immunization regimen using the recombinant P139-512 fragment, expressed and purified from a Bacillus subtilis strain. The P139-512 protein comprises amino acids that encompasses the entire A region and a small portion of the variable region of the P1 protein. We used spores of B. subtilis 1012 (wild-strain) and recombinants that were modified to express the antigen P139-512 (LDV702). In addition to express the antigen, the LDV704 strain was modified to express a surface-exposed bacterial invasin (InvA) capable of binding to the mucosal epithelia. BALB/c mice were primed via the sublingual route with a dose of B. subtilis spores (1012, LDV702, or LDV704 strains) followed by two boosting doses with the purified protein P139-512, associated or not with the LTK63 adjuvant, by the same administration route. Significant serum antibody levels were induced by the formulations with the adjuvants after the third dose and the antibodies were shown to recognize epitopes exposed on the surface of different S. mutans strains. However, none of the formulations were capable to activate mucosal responses (S-IgA). Nevertheless, we observed that the LTK63 enhanced the serum IgG responses and qualitatively improved the induced antibody response. Thus, the administration of the formulations in the presence of the adjuvant represents a promising alternative for the control of S. mutans.